Compare TYGO & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYGO | XOMA |
|---|---|---|
| Founded | 2007 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.4M | 308.6M |
| IPO Year | 2021 | N/A |
| Metric | TYGO | XOMA |
|---|---|---|
| Price | $3.43 | $26.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $60.60 |
| AVG Volume (30 Days) | ★ 418.0K | 118.2K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $54,014,000.00 | N/A |
| Revenue This Year | $27.36 | $76.93 |
| Revenue Next Year | $25.52 | $29.28 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $18.40 |
| 52 Week High | $4.50 | $39.92 |
| Indicator | TYGO | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 50.33 |
| Support Level | $3.19 | $23.92 |
| Resistance Level | $4.41 | $27.61 |
| Average True Range (ATR) | 0.39 | 1.47 |
| MACD | -0.06 | 0.12 |
| Stochastic Oscillator | 21.87 | 47.54 |
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.